Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMUP516)

Drug Name
L-873724 Drug Info
Synonyms
L-873724; UNII-29250PP3ON; 603139-12-4; CHEMBL437501; 29250PP3ON; (2S)-N-(cyanomethyl)-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]ethyl]amino]Pentanamide; (2S)-N-(cyanomethyl)-4-methyl-2-[[(1S)-2,2,2-trifluoro-1-[4-(4-methylsulfonylphenyl)phenyl]ethyl]amino]pentanamide; VYFDSJLOCIGIKP-SFTDATJTSA-N; GTPL7860; SCHEMBL2157182; BDBM19489; (+)-L-873724; ZINC34802820; CS-6814; HY-50887; Pentanamide, N-(cyanomethyl)-4-methyl-2-(((1S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)eth
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Investigative [1]
Cross-matching ID
PubChem CID
9913088
CAS Number
CAS 603139-12-4
TTD Drug ID
DMUP516

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Cathepsin K (CTSK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Odanacatib DM1EO3G Osteoporosis FB83.0 Phase 3 [4]
SAR-114137 DMZ1XR5 Pain MG30-MG3Z Phase 1 [5]
VEL-0230 DMDSC63 Rheumatoid arthritis FA20 Phase 1 [6]
PMID27998201-Compound-12 DM8QZNC Bone cancer 2B5Z Patented [7]
PMID27998201-Compound-5 DMVZ0ND Chronic obstructive pulmonary disease CA22 Patented [7]
PMID27998201-Compound-9 DM1JOZN Rheumatoid arthritis FA20 Patented [7]
PMID25399719-Compound-17 DMRXKJZ N. A. N. A. Patented [8]
PMID27998201-Compound-15 DMOB8LU Pain MG30-MG3Z Patented [7]
Oxotetrahydro-2-H-furo[3.2-b]pyrrol-4(5-H)-yl derivative 1 DM1SH5R Pain MG30-MG3Z Patented [7]
PMID27998201-Compound-8 DMZK0SY N. A. N. A. Patented [7]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Cathepsin L (CTSL)
Drug Name Drug ID Indication ICD 11 Highest Status REF
KGP94 DM2NZ6K Coagulation defect 3B10.0 Clinical trial [9]
PMID27998201-Compound-12 DM8QZNC Bone cancer 2B5Z Patented [7]
PMID27998201-Compound-5 DMVZ0ND Chronic obstructive pulmonary disease CA22 Patented [7]
PMID27998201-Compound-9 DM1JOZN Rheumatoid arthritis FA20 Patented [7]
PMID25399719-Compound-17 DMRXKJZ N. A. N. A. Patented [8]
PMID27998201-Compound-17 DMAZVHJ Hair loss ED70 Patented [7]
Phenylalanine derivative 1 DMVYP8K Glioma 2A00.0 Patented [7]
PMID27998201-Compound-7 DMU4QYR Abdominal aortic aneurysm BD50.4 Patented [7]
PMID27998201-Compound-6 DM0LGTY N. A. N. A. Patented [7]
PMID27998201-Compound-1 DM5QH4C Coronavirus infection 1D92 Patented [7]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Cathepsin B (CTSB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID27998201-Compound-12 DM8QZNC Bone cancer 2B5Z Patented [7]
PMID27998201-Compound-5 DMVZ0ND Chronic obstructive pulmonary disease CA22 Patented [7]
PMID27998201-Compound-9 DM1JOZN Rheumatoid arthritis FA20 Patented [7]
PMID27998201-Compound-17 DMAZVHJ Hair loss ED70 Patented [7]
PMID27998201-Compound-11 DMTV5NU Metastatic cancer 2D50-2E2Z Patented [7]
PMID27998201-Compound-2 DMMAE3C Alzheimer disease 8A20 Patented [7]
PMID27998201-Compound-22 DMS9QA7 Alzheimer disease 8A20 Patented [7]
PMID27998201-Compound-13 DMZHIM8 Hepatic fibrosis DB93.0 Patented [7]
Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1 DMZ4B3W Cerebral ischemia 8B11 Patented [7]
PMID27998201-Compound-24 DM25BNZ Glioma 2A00.0 Patented [7]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Cathepsin S (CTSS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
RG7625 DMDGPKS Autoimmune disease 4A40-4A45 Phase 2 [10]
SAR-114137 DMZ1XR5 Pain MG30-MG3Z Phase 1 [5]
VBY- 891 DMTKPH4 Autoimmune diabetes 5A10 Phase 1 [11]
VBY- 036 DMULRYC Neuropathic pain 8E43.0 Phase 1 [12]
VBY-129 DM4YIWK Autoimmune diabetes 5A10 Phase 1 [13]
PMID27998201-Compound-12 DM8QZNC Bone cancer 2B5Z Patented [7]
PMID27998201-Compound-5 DMVZ0ND Chronic obstructive pulmonary disease CA22 Patented [7]
PMID27998201-Compound-9 DM1JOZN Rheumatoid arthritis FA20 Patented [7]
PMID25399719-Compound-17 DMRXKJZ N. A. N. A. Patented [8]
PMID27998201-Compound-17 DMAZVHJ Hair loss ED70 Patented [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cathepsin B (CTSB) TTF2LRI CATB_HUMAN Inhibitor [2]
Cathepsin K (CTSK) TTDZN01 CATK_HUMAN Inhibitor [3]
Cathepsin L (CTSL) TT36ETB CATL1_HUMAN Inhibitor [2]
Cathepsin S (CTSS) TTUMQVO CATS_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7860).
2 The identification of potent, selective, and bioavailable cathepsin S inhibitors. Bioorg Med Chem Lett. 2007 Sep 1;17(17):4929-33.
3 The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008 Feb 1;18(3):923-8.
4 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
5 From laboratory to pilot plant: the solid-state process development of a highly potent cathepsin S/K inhibitor. Eur J Pharm Biopharm. 2013 Apr;83(3):436-48.
6 Discovery and parallel synthesis of a new class of cathepsin K inhibitors. Bioorg Med Chem Lett. 2001 Nov 19;11(22):2951-4.
7 Cathepsin B and L inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2017 Jun;27(6):643-656.
8 An updated patent review of calpain inhibitors (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):17-31.
9 Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6610-5.
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2353).
12 Clinical pipeline report, company report or official report of ViroBay.
13 Clinical pipeline report, company report or official report of ViroBay.